The Silvant Large Cap Growth SMA delivered strong returns in the fourth quarter of 2025, outperforming its benchmark. This success was primarily fueled by strategic investments in healthcare, communication services, financials, and industrials. However, the portfolio also experienced some setbacks from specific stock underperformers.

Eli Lilly and Alphabet were key drivers of the positive performance, benefiting from their strong market positions and growth initiatives. The commentary provides an overview of the factors influencing the portfolio's results, including both the top contributors and detractors, offering insights into the investment strategy and market dynamics of the period.

Q4 2025 Performance Overview

In the fourth quarter of 2025, the Silvant Large Cap Growth SMA demonstrated impressive financial results, achieving a gross return of +2.69% and a net return of +1.94%. This performance notably surpassed the Russell 1000 Growth Index, which posted a return of +1.12% for the same period. The robust returns indicate a successful investment strategy that capitalized on favorable market conditions and astute stock selections within key economic sectors. The outperformance against the benchmark underscores the effectiveness of the portfolio management in navigating market fluctuations and generating superior returns for investors.

The strong performance of the Silvant Large Cap Growth SMA in Q4 2025 was a testament to its well-executed investment approach. The portfolio's gross return of +2.69% and net return of +1.94% significantly outpaced the Russell 1000 Growth Index's +1.12%, highlighting a period of substantial growth. This positive divergence from the benchmark was largely attributable to strategic allocations and favorable stock-specific developments across several vital sectors, including healthcare, communication services, financials, and industrials. These sectors collectively provided significant uplift, showcasing the portfolio's ability to identify and leverage growth opportunities while effectively managing risk in a dynamic market environment.

Key Performance Drivers and Detractors

During the fourth quarter of 2025, the Silvant Large Cap Growth SMA's strong performance was significantly bolstered by several top-contributing stocks, with Eli Lilly and Alphabet leading the charge. These companies demonstrated robust growth and positive market sentiment, playing a crucial role in the portfolio's outperformance. Conversely, certain investments acted as detractors, notably Royal Caribbean and O'Reilly Automotive. These stocks experienced headwinds during the quarter, tempering some of the gains made by the top performers, and highlighting the inherent volatility and sector-specific challenges within the broader market.

The successful navigation of the market landscape by the Silvant Large Cap Growth SMA in Q4 2025 was evident in the distinct impact of its key holdings. Eli Lilly's contributions were particularly impactful, reflecting strong operational performance or positive market re-ratings. Similarly, Alphabet's performance underscored its continued innovation and market dominance in the communication services sector. However, the portfolio also faced challenges from underperforming assets such as Royal Caribbean, which may have been affected by sector-specific downturns, and O'Reilly Automotive, indicating potential industry shifts or company-specific issues. These movements collectively illustrate the complex interplay of individual stock performance and broader market trends in shaping overall portfolio returns.